Endogenous salivary inhibitors of Human Immunodeficiency Virus

被引:45
|
作者
Shugars, DC [1 ]
Alexander, AL
Fu, K
Freel, SA
机构
[1] Univ N Carolina, Sch Dent, Dept Dent Ecol, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dent Res Ctr, Chapel Hill, NC 27599 USA
关键词
human immunodeficiency virus; AIDS; inhibitors; secretory leucocyte protease inhibitor; saliva;
D O I
10.1016/S0003-9969(99)00003-5
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) is rarely transmitted through salivary secretions, due in part to the presence of endogenous inhibitors. Here, the protective characteristics of the intraoral environment are summarized and inhibitory factors that reduce HIV-1 infectivity in vitro described, focusing on secretory leucocyte protease inhibitor (SLPI), a 12-kDa mucosal protein that blocks HIV infection in several cell-culture systems. SLPI appears to interact with a cellular surface molecule to limit viral entry into target cells. To determine whether the inhibitor has a similar role in vivo, the contribution of salivary SLPI to anti-HIV-1 activity was assessed. Whole unstimulated filtered salivas from infected and uninfected donors contained similar concentrations of the inhibitor, Depletion from SLPI filtered saliva produced a corresponding loss of inhibitory activity. In general, filtered whole salivas obtained from 10 donors had antiviral activities that correlated positively with SLPI concentrations. However, some samples having SLPI well below the concentration required for inhibitory activity in vitro exhibited modest inhibition, suggesting the presence of other anti-HIV-1 components in oral fluids. Thus, SLPI is a major but not sole inhibitor of this virus in saliva. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:445 / 453
页数:9
相关论文
共 50 条
  • [31] The Surgeon and Human Immunodeficiency Virus
    Jens Mielke
    Kazadi K.N. Kalangu
    World Journal of Surgery, 2003, 27 : 967 - 971
  • [32] Man-made inhibitors of transcription factors involved in the replication of human immunodeficiency virus
    Fujita, M
    Otsuka, M
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1997, 55 (08) : 697 - 704
  • [33] New first and second generation inhibitors of human immunodeficiency virus-1 integrase
    Pendri, Annapurna
    Meanwell, Nicholas A.
    Peese, Kevin M.
    Walker, Michael A.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (08) : 1173 - 1189
  • [34] Human Immunodeficiency Virus and Uveitis
    Yang, Mingming
    Kamoi, Koju
    Zong, Yuan
    Zhang, Jing
    Ohno-Matsui, Kyoko
    VIRUSES-BASEL, 2023, 15 (02):
  • [35] Human Immunodeficiency Virus and Leishmaniasis
    Ezra, Navid
    Ochoa, Maria Teresa
    Craft, Noah
    JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2010, 2 (03) : 248 - 257
  • [36] Human Immunodeficiency Virus Medicine
    Gallant, Joel E.
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S624 - S625
  • [37] Human immunodeficiency virus and lymphoma
    Tazi, Illias
    Lahlimi, Fatima Zahra
    BULLETIN DU CANCER, 2021, 108 (10) : 953 - 962
  • [38] Human Immunodeficiency Virus in Pregnancy
    Dude, Annie M.
    Jones, Maura
    Wilson, Tenisha
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2023, 50 (02) : 389 - 399
  • [39] Management of sarcomatoid salivary duct carcinoma of the submandibular gland duct with coexisting seropositive human immunodeficiency virus
    Mourad, W. F.
    Hu, K. S.
    Shourbaji, R. A.
    Harrison, L. B.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2013, 127 (06) : 621 - 624
  • [40] Management of anticoagulation in patients with human immunodeficiency virus/acquired immunodeficiency virus*
    Sabourin, Ashley A.
    Patel, Twisha
    Saad, Samira
    Renner, Elizabeth
    Mouland, Erin
    Adie, Sarah
    Ha, Nghi B.
    THROMBOSIS RESEARCH, 2021, 200 : 102 - 108